Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck

Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck

Dacomitinib, an irreversible pan-HER inhibitor, had shown modest clinical activity in squamous cell carcinoma of head and neck (SCCHN) patients. Therefore, validated predictive biomarkers are required to identify patients most likely to benefit from this therapeutic option. To characterize the genet...

Full description

Bibliographic Details
Main Authors: Huang, Kie Kyon, Jang, Kang Won, Kim, Sangwoo, Kim, Han Sang, Kim, Sung-Moo, Kwon, Hyeong Ju, Kim, Hye Ryun, Yun, Hwan Jung, Ahn, Myung Ju, Park, Keon Uk, Ramnarayanan, Kalpana, McPherson, John R., Zhang, Shenli, Rhee, Je-Keun, Vettore, André L., Das, Kakoli, Ishimoto, Takatsugu, Kim, Joo Hang, Koh, Yoon Woo, Kim, Se Hun, Choi, Eun Chang, Teh, Bin Tean, Rozen, Steven G., Kim, Tae-Min, Tan, Patrick, Cho, Byoung Chul
Format: Online
Language:English
Published: Nature Publishing Group 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726344/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726344/

Similar Items